It has been well documented that anti-HER2 monoclonal antibodies (e.g., trastuzumab) improve overall survival (primary goal) and pathological complete response rates (surrogate result) in patients with luminal B2 or HER2-enriched breast cancers .22 The gene discussed is ERBB2; the disease is breast cancer.